TGTX
TGTX
NASDAQ · Biotechnology

Tg Therapeutics Inc

$42.86
-0.17 (-0.38%)
As of May 9, 1:19 AM ET ·
Financial Highlights (FY 2026)
Revenue
582.44M
Net Income
422.62M
Gross Margin
83.7%
Profit Margin
72.6%
Rev Growth
+504.9%
D/E Ratio
1.10
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 83.7% 67.6% 67.6% 67.6%
Operating Margin 20.0% 11.4% 11.2% 12.8%
Profit Margin 72.6% 12.5% 12.7% 11.0%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 582.44M 1.04B 1.08B 956.87M
Gross Profit 487.27M 701.79M 727.04M 646.94M
Operating Income 116.55M 118.01M 120.46M 122.04M
Net Income 422.62M 129.57M 136.18M 105.42M
Gross Margin 83.7% 67.6% 67.6% 67.6%
Operating Margin 20.0% 11.4% 11.2% 12.8%
Profit Margin 72.6% 12.5% 12.7% 11.0%
Rev Growth +504.9% +16.6% +24.3% +11.8%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 1.71B 908.15M 880.79M 975.86M
Total Equity 1.56B 2.79B 2.78B 2.56B
D/E Ratio 1.10 0.33 0.32 0.38
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA 126.81M 169.61M 170.48M 149.89M
Free Cash Flow 110.01M 140.89M 136.27M